AU2005234596B8 - Piperazinylpiperidine derivatives as chemokine receptor antagonists - Google Patents

Piperazinylpiperidine derivatives as chemokine receptor antagonists Download PDF

Info

Publication number
AU2005234596B8
AU2005234596B8 AU2005234596A AU2005234596A AU2005234596B8 AU 2005234596 B8 AU2005234596 B8 AU 2005234596B8 AU 2005234596 A AU2005234596 A AU 2005234596A AU 2005234596 A AU2005234596 A AU 2005234596A AU 2005234596 B8 AU2005234596 B8 AU 2005234596B8
Authority
AU
Australia
Prior art keywords
alkyl
compound
dihydro
inden
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
AU2005234596A
Other languages
English (en)
Other versions
AU2005234596A1 (en
AU2005234596A8 (en
AU2005234596B2 (en
Inventor
Rajan Anand
Ganfeng Cao
Lihua Chen
Joseph Glenn
Taisheng Huang
David Meloni
Brian Metcalf
Anlai Wang
Chu-Biao Xue
Ke Zhang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Incyte Holdings Corp
Original Assignee
Incyte Holdings Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Incyte Holdings Corp filed Critical Incyte Holdings Corp
Publication of AU2005234596A1 publication Critical patent/AU2005234596A1/en
Application granted granted Critical
Publication of AU2005234596B2 publication Critical patent/AU2005234596B2/en
Publication of AU2005234596A8 publication Critical patent/AU2005234596A8/en
Publication of AU2005234596B8 publication Critical patent/AU2005234596B8/en
Assigned to INCYTE HOLDINGS CORPORATION reassignment INCYTE HOLDINGS CORPORATION Request for Assignment Assignors: INCYTE CORPORATION
Anticipated expiration legal-status Critical
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)
AU2005234596A 2004-04-13 2005-04-12 Piperazinylpiperidine derivatives as chemokine receptor antagonists Expired AU2005234596B8 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US56169704P 2004-04-13 2004-04-13
US60/561,697 2004-04-13
US57222104P 2004-05-18 2004-05-18
US60/572,221 2004-05-18
PCT/US2005/012265 WO2005101838A2 (en) 2004-04-13 2005-04-12 Piperazinylpiperidine derivatives as chemokine receptor antagonists

Publications (4)

Publication Number Publication Date
AU2005234596A1 AU2005234596A1 (en) 2005-10-27
AU2005234596B2 AU2005234596B2 (en) 2011-06-02
AU2005234596A8 AU2005234596A8 (en) 2011-06-16
AU2005234596B8 true AU2005234596B8 (en) 2011-06-16

Family

ID=35150660

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2005234596A Expired AU2005234596B8 (en) 2004-04-13 2005-04-12 Piperazinylpiperidine derivatives as chemokine receptor antagonists

Country Status (20)

Country Link
US (4) US7678798B2 (enExample)
EP (1) EP1734966B1 (enExample)
JP (2) JP4948395B2 (enExample)
KR (1) KR101235090B1 (enExample)
CN (1) CN103012374B (enExample)
AU (1) AU2005234596B8 (enExample)
BR (1) BRPI0509803A (enExample)
CA (1) CA2562235C (enExample)
CR (1) CR8680A (enExample)
EA (1) EA015517B1 (enExample)
EC (1) ECSP066925A (enExample)
ES (1) ES2431524T3 (enExample)
GE (1) GEP20094680B (enExample)
HU (1) HU229709B1 (enExample)
IL (1) IL178622A (enExample)
MX (1) MXPA06011722A (enExample)
NO (1) NO337788B1 (enExample)
NZ (1) NZ550370A (enExample)
RU (1) RU2369604C2 (enExample)
WO (1) WO2005101838A2 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GEP20115290B (en) * 2002-11-27 2011-09-26 Incyte Corp 3-aminopyrrolidine derivatives as modulators of chemokine receptors
BRPI0509803A (pt) * 2004-04-13 2007-09-18 Incyte Corp derivados de piperazinilpiperidina como antagonistas de receptor de quimiocina
WO2006071875A1 (en) 2004-12-29 2006-07-06 Millennium Pharmaceuticals, Inc. Compounds useful as chemokine receptor antagonists
US7635698B2 (en) 2004-12-29 2009-12-22 Millennium Pharmaceuticals, Inc. Compounds useful as chemokine receptor antagonists
US7910108B2 (en) 2006-06-05 2011-03-22 Incyte Corporation Sheddase inhibitors combined with CD30-binding immunotherapeutics for the treatment of CD30 positive diseases
WO2008030853A2 (en) * 2006-09-06 2008-03-13 Incyte Corporation Combination therapy for human immunodeficiency virus infection
CN101293820B (zh) * 2007-04-27 2012-10-10 天津药明康德新药开发有限公司 5-三氟甲基-1-茚酮的合成方法
WO2009012259A1 (en) * 2007-07-16 2009-01-22 Incyte Corporation Pentafluorosulfanyl-substituted piperazinylpiperidine derivatives as chemokine receptor antagonists
WO2010081851A1 (en) 2009-01-14 2010-07-22 Genoscience Pharma Piperidin-4-ylpiperazine compounds for the treatment of hcv infection
KR101374409B1 (ko) 2011-10-17 2014-03-18 성균관대학교산학협력단 비유전성 항생제 내성 저해제 및 이의 용도
KR102114536B1 (ko) 2015-05-07 2020-05-22 브리스톨-마이어스 스큅 컴퍼니 RORγ 조정제로서의 트리시클릭 술폰
JP2019529522A (ja) 2016-10-10 2019-10-17 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ ＲＯＲγ調節因子としての三環式スルホン類
WO2018073248A1 (en) 2016-10-17 2018-04-26 Icm (Institut Du Cerveau Et De La Moelle Épinière) Prognosis of demyelinating diseases patients and treatment thereof

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1047776C (zh) * 1993-10-01 1999-12-29 诺瓦蒂斯有限公司 具有药理学活性的吡啶类衍生物及其制备方法
WO1995015973A1 (en) 1993-12-06 1995-06-15 Cytel Corporation Cs-1 peptidomimetics, compositions and methods of using the same
US5510332A (en) 1994-07-07 1996-04-23 Texas Biotechnology Corporation Process to inhibit binding of the integrin α4 62 1 to VCAM-1 or fibronectin and linear peptides therefor
WO1996001644A1 (en) 1994-07-11 1996-01-25 Athena Neurosciences, Inc. Inhibitors of leukocyte adhesion
US5811391A (en) 1994-08-25 1998-09-22 Cytel Corporation Cyclic CS-1 peptidomimetics, compositions and methods of using same
GB9524630D0 (en) 1994-12-24 1996-01-31 Zeneca Ltd Chemical compounds
AU5259296A (en) 1995-04-07 1996-10-23 Warner-Lambert Company Flavones and coumarins as agents for the treatment of athero sclerosis
NZ321575A (en) 1995-10-30 1999-05-28 Janssen Pharmaceutica Nv 1-(1,2-disubstituted piperidinyl)-4- substituted piperazine derivatives
GB9522372D0 (en) 1995-11-01 1996-01-03 Merck Sharp & Dohme Therapeutic agents
US5704960A (en) 1995-12-20 1998-01-06 Corning, Inc. Method of forming an optical fiber for reduced polarization effects in amplifiers
GB9603741D0 (en) 1996-02-22 1996-04-24 Lin Mei Treatment of water by electrolysis
DE69715865T2 (de) 1996-07-01 2003-08-07 Schering Corp., Kenilworth Muscarin-antagonisten
US5935958A (en) * 1996-07-01 1999-08-10 Schering Corporation Muscarinic antagonists
AU729415B2 (en) 1996-07-12 2001-02-01 Millennium Pharmaceuticals, Inc. Chemokine receptor antagonists and methods of use therefor
EP1001764A4 (en) 1997-05-29 2005-08-24 Merck & Co Inc HETEROCYCLIC AMIDE COMPOUNDS AS INHIBITORS OF CELL ADHESION
AU726585B2 (en) 1997-05-29 2000-11-09 Merck & Co., Inc. Biarylalkanoic acids as cell adhesion inhibitors
DE69820614T2 (de) 1997-05-30 2004-09-30 Celltech Therapeutics Ltd., Slough Entzündungshemmende tyrosin-derivate
JP2001517246A (ja) 1997-06-23 2001-10-02 田辺製薬株式会社 α▲下４▼β▲下１▼媒介細胞接着の阻止剤
US6312689B1 (en) 1998-07-23 2001-11-06 Millennium Pharmaceuticals, Inc. Anti-CCR2 antibodies and methods of use therefor
US6635646B1 (en) 1999-05-04 2003-10-21 Schering Corporation Pegylated interferon alfa-CCR5 antagonist combination HIV therapy
PT1175402E (pt) 1999-05-04 2005-11-30 Schering Corp Derivados da piperidina uteis como antagonistas ccr5
US6387930B1 (en) 1999-05-04 2002-05-14 Schering Corporation Piperidine derivatives useful as CCR5 antagonists
CA2371583C (en) 1999-05-04 2005-09-13 Schering Corporation Piperazine derivatives useful as ccr5 antagonists
US7825121B2 (en) 1999-05-04 2010-11-02 Schering Corporation Piperazine derivatives useful as CCR5 antagonists
US6391865B1 (en) 1999-05-04 2002-05-21 Schering Corporation Piperazine derivatives useful as CCR5 antagonists
ES2165274B1 (es) 1999-06-04 2003-04-01 Almirall Prodesfarma Sa Nuevos derivados de indolilpiperidina como agentes antihistaminicos y antialergicos.
CN1253435C (zh) 2001-03-29 2006-04-26 先灵公司 可用作ccr5拮抗剂的芳基肟－哌嗪
DK1373256T3 (da) 2001-03-29 2005-10-10 Schering Corp CCR5-antagonister, der er nyttige til behandling af AIDS
AR036366A1 (es) 2001-08-29 2004-09-01 Schering Corp Derivados de piperidina utiles como antagonistas de ccr5, composiciones farmaceuticas, el uso de dichos derivados para la fabricación de un medicamento y un kit
SE0103818D0 (sv) 2001-11-15 2001-11-15 Astrazeneca Ab Chemical compounds
JP2005518424A (ja) 2001-11-29 2005-06-23 シェーリング　コーポレイション Ａｉｄｓおよび関連するｈｉｖ感染の処置のためのｃｃｒ５−アンタゴニストとしての４（（ｚ）−（４−ブロモフェニル）エトキシイミノ）メチル）−１’−（（２，４−ジメチル−１−オキシド−３−ピリジニルカルボニル）−４’−メチル−１，４’ビピペリジンの薬学的塩の調製
AU2003207646C1 (en) 2002-01-22 2008-09-18 Vanderbilt University Treating stress response with chemokine receptor CCR5 modulators
CN100396676C (zh) * 2002-03-29 2008-06-25 先灵公司 作为ccr5拮抗药的哌啶和哌嗪化合物的合成
MXPA05000081A (es) 2002-06-27 2005-04-11 Schering Ag Quinolinas sustituidas antagonistas del receptor ccr5.
GB0223223D0 (en) 2002-10-07 2002-11-13 Novartis Ag Organic compounds
WO2004056772A1 (en) 2002-12-23 2004-07-08 Janssen Pharmaceutica N.V. Substituted 1,4-di-piperidin-4-yl-piperazine derivatives and their use as tachykinin antagonists
MY141736A (en) 2002-10-08 2010-06-15 Elanco Animal Health Ireland Substituted 1,4-di-piperidin-4-yi-piperazine derivatives and their use as neurokinin antagonists
GEP20115290B (en) 2002-11-27 2011-09-26 Incyte Corp 3-aminopyrrolidine derivatives as modulators of chemokine receptors
ATE409065T1 (de) 2002-12-17 2008-10-15 Schering Corp Inhibitoren der 17 beta- hydroxysteroiddehydrogenase des typs 3 zur behandlung androgenabhängiger krankheiten
PE20040769A1 (es) 2002-12-18 2004-11-06 Schering Corp Derivados de piperidina utiles como antagonisas ccr5
EP1581517B1 (en) 2002-12-23 2007-02-21 Janssen Pharmaceutica N.V. Substituted 1-piperidin-4-yl-4-azetidin-3-yl-piperazine derivatives and their use as neurokinin antagonists
JO2485B1 (en) 2002-12-23 2009-01-20 شركة جانسين فارماسوتيكا ان. في 1-Piperidine-3-Yl-4-Piperidine-4-Yl-Piperazine derivatives substituted and used as quinine antagonists
JO2696B1 (en) 2002-12-23 2013-03-03 شركة جانسين فارماسوتيكا ان. في Derivatives of 1-piperdine-4-yl-4-biprolidine-3-yl-piperazine substituted and used as quinine antagonists
CA2509090C (en) 2002-12-23 2012-01-24 Janssen Pharmaceutica N.V. Substituted 4-(4-piperidin-4-yl-piperazin-1-yl)-azepane derivatives and their use as neurokinin antagonists
WO2004087685A2 (en) 2003-03-31 2004-10-14 Janssen Pharmaceutica N.V. Phospholipase c inhibitors for use in treating inflammatory disorders
ATE395062T1 (de) 2003-06-10 2008-05-15 Janssen Pharmaceutica Nv Kombination von opioiden und einem piperazin- derivat für die behandlung von schmerzen
WO2004113323A1 (en) 2003-06-13 2004-12-29 Schering Aktiengesellschaft Quinolyl amide derivatives as ccr-5 antagonists
WO2005005419A1 (en) 2003-06-30 2005-01-20 Schering Corporation Mch antagonists for the treatment of obesity
US7652142B2 (en) 2003-11-03 2010-01-26 Schering Corporation Bipiperidinyl derivatives useful as inhibitors of chemokine receptors
WO2005060665A2 (en) 2003-12-18 2005-07-07 Incyte Corporation 3-cycloalkylaminopyrrolidine derivatives as modulators of chemokine receptors
BRPI0509803A (pt) 2004-04-13 2007-09-18 Incyte Corp derivados de piperazinilpiperidina como antagonistas de receptor de quimiocina
CA2565486A1 (en) 2004-05-11 2005-12-08 Incyte Corporation 3-(4-heteroarylcyclohexylamino)cyclopentanecarboxamides as modulators of chemokine receptors
GEP20094844B (en) 2004-06-28 2009-11-25 Incyte Corp 3-aminocyclopentane carboxamides as modulators of chemokine receptors
EP1763351B9 (en) 2004-06-28 2017-05-31 Incyte Holdings Corporation 3-aminocyclopentanecarboxamides as modulators of chemokine receptors
WO2006071875A1 (en) 2004-12-29 2006-07-06 Millennium Pharmaceuticals, Inc. Compounds useful as chemokine receptor antagonists
US7635698B2 (en) 2004-12-29 2009-12-22 Millennium Pharmaceuticals, Inc. Compounds useful as chemokine receptor antagonists
JP2008526863A (ja) 2005-01-06 2008-07-24 シェーリング コーポレイション Ｃｃ５ｒ受容体アンタゴニストの合成
WO2006088836A2 (en) 2005-02-16 2006-08-24 Schering Corporation Piperazine-piperidines with cxcr3 antagonist activity
MX2007009945A (es) 2005-02-16 2007-09-26 Schering Corp Piperazinas sustituidas con heterociclicos con actividad antagonista de cxcr3.
CA2598459A1 (en) * 2005-02-16 2006-08-24 Schering Corporation Novel heterocyclic substituted pyridine or phenyl compounds with cxcr3 antagonist activity
EP1856097B1 (en) 2005-02-16 2012-07-11 Schering Corporation Pyridyl and phenyl substituted piperazine-piperidines with cxcr3 antagonist activity
MX2007009949A (es) 2005-02-16 2007-09-26 Schering Corp Pirazinil-piperazin-piperidinas sustituidas con heteroarilo con actividad antagonista de cxcr3.
RU2007134260A (ru) 2005-02-16 2009-03-27 Шеринг Корпорейшн (US) Пиразинилзамещенные пиперазин-пиперидины с антагонистической активностью в отношении cxcr3
CA2598460C (en) 2005-02-16 2013-05-07 Schering Corporation Amine-linked pyridyl and phenyl substituted piperazine-piperidines with cxcr3 antagonist activity
MX2007010258A (es) 2005-02-23 2007-09-11 Schering Corp Derivados de piperidinil piperazina utiles como inhibidores de receptores de quimiocina.
CA2598568A1 (en) 2005-02-23 2006-08-31 Schering Corporation Piperidinyl piperidine derivatives useful as inhibitors of chemokine receptors
MEP1008A (xx) 2005-12-21 2010-02-10 Incyte Corp 3-aminociklopentankarboksamidi kao modulatori receptora hemokina
TW200745087A (en) 2006-02-24 2007-12-16 Schering Corp CCR5 antagonists useful for treating HIV
WO2008030853A2 (en) 2006-09-06 2008-03-13 Incyte Corporation Combination therapy for human immunodeficiency virus infection

Also Published As

Publication number Publication date
IL178622A (en) 2012-10-31
RU2369604C2 (ru) 2009-10-10
RU2006139946A (ru) 2008-05-20
EP1734966B1 (en) 2013-07-31
EA015517B1 (ru) 2011-08-30
IL178622A0 (en) 2007-02-11
US20140155404A1 (en) 2014-06-05
WO2005101838A8 (en) 2006-05-11
EA200601894A1 (ru) 2007-02-27
EP1734966A2 (en) 2006-12-27
US8268826B2 (en) 2012-09-18
JP2012036210A (ja) 2012-02-23
AU2005234596A1 (en) 2005-10-27
HUP0600858A2 (en) 2008-10-28
ECSP066925A (es) 2006-12-20
KR20070008635A (ko) 2007-01-17
MXPA06011722A (es) 2007-01-25
NO337788B1 (no) 2016-06-20
WO2005101838A3 (en) 2006-03-02
AU2005234596A8 (en) 2011-06-16
HU229709B1 (en) 2014-05-28
ES2431524T3 (es) 2013-11-26
KR101235090B1 (ko) 2013-02-20
US7678798B2 (en) 2010-03-16
NO20065151L (no) 2007-01-04
EP1734966A4 (en) 2009-04-22
CR8680A (es) 2007-08-28
JP2007532654A (ja) 2007-11-15
BRPI0509803A (pt) 2007-09-18
WO2005101838A2 (en) 2005-10-27
US20090197887A1 (en) 2009-08-06
JP4948395B2 (ja) 2012-06-06
NZ550370A (en) 2009-09-25
CA2562235A1 (en) 2005-10-27
CA2562235C (en) 2013-09-24
US20050261310A1 (en) 2005-11-24
GEP20094680B (en) 2009-05-10
US9067921B2 (en) 2015-06-30
US8680104B2 (en) 2014-03-25
US20120295912A1 (en) 2012-11-22
CN103012374B (zh) 2015-05-20
CN103012374A (zh) 2013-04-03
AU2005234596B2 (en) 2011-06-02

Similar Documents

Publication Publication Date Title
US9067921B2 (en) Piperazinylpiperidine derivatives as chemokine receptor antagonists
US8563582B2 (en) 3-aminocyclopentanecarboxamides as modulators of chemokine receptors
US20100203039A1 (en) 3-aminocyclopentanecarboxamides as modulators of chemokine receptors
WO2009012259A1 (en) Pentafluorosulfanyl-substituted piperazinylpiperidine derivatives as chemokine receptor antagonists

Legal Events

Date Code Title Description
TH Corrigenda

Free format text: IN VOL 20, NO 41, PAGE(S) 4030 UNDER THE HEADING PCT APPLICATIONS THAT HAVE ENTERED THE NATIONAL PHASE - NAME INDEX UNDER THE NAME INCYTE CORPORATION, APPLICATION NO. 2005234596, UNDER INID (54) CORRECT THE TITLE TO READ PIPERAZINYLPIPERIDINE DERIVATIVES AS CHEMOKINE RECEPTOR ANTAGONISTS

Free format text: IN VOL 25, NO 21, PAGE(S) 2710 UNDER THE HEADING APPLICATIONS ACCEPTED - NAME INDEX UNDER THE NAME INCYTE CORPORATION, APPLICATION NO. 2005234596, UNDER INID (54) CORRECT THE TITLE TO READ PIPERAZINYLPIPERIDINE DERIVATIVES AS CHEMOKINE RECEPTOR ANTAGONISTS

FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: INCYTE HOLDINGS CORPORATION

Free format text: FORMER OWNER WAS: INCYTE CORPORATION

MK14 Patent ceased section 143(a) (annual fees not paid) or expired